What doesn't hold up

Popular claims and products for ADHD that the trials do not back. Not ranked, not tailored.

• Not supported

  Sugar causes ADHD

  Not rated

  Not an established cause; blinded trials don't show behaviour getting worse overall.

  What holds up instead: Make regular meals easier Request your child's ADHD assessment

  What the trials found

  • Across 23 blinded sugar challenge studies in children, a meta-analysis found no clear effect on behaviour or cognition, though it could not exclude small effects in some children.
  • A 2026 review did find associations between sugary diets and ADHD outcomes, but confounding and the limited number of studies that isolate sugar rule out a causal conclusion.
  • The older trials address immediate effects, not whether years of eating sugar influence how ADHD develops.

  Sources

  • Tier 2 studyThe effect of sugar on behavior or cognition in children. A meta-analysisJAMA, 1995
  • Tier 2 studyDietary Carbohydrates and ADHD Symptoms: A Systematic ReviewNutrients, 2026
• Not supported

  ADHD is caused by bad parenting

  Not rated

  ADHD is a developmental condition. Blaming parents doesn't explain it.

  What holds up instead: Ask about parent behaviour training

  What the trials found

  • NIMH says genes play a large role and ADHD probably comes from a combination of factors, and the NHS says it often runs in families.
  • An NHS trust leaflet for parents points out that parents of children with ADHD can be wrongly accused of bad parenting, and explains that support and behaviour management skills help at home.
  • Family circumstances can affect how a child copes, but that does not make ADHD a parental failure.

  Sources

  • Tier 1 guidelineAttention Deficit/Hyperactivity Disorder: What You Need to KnowNIMH, 2024
  • Tier 1 guidelineAn introduction to ADHDKent Community Health NHS Foundation Trust, 2023
  • Tier 1 guidelineADHD in children and young peopleNHS, 2025
• No better than placebo

  Omega-3 fish oil supplements treat ADHD

  Low certainty

  Children and teens: omega-3 did no better than placebo on parent-rated symptoms.

  What holds up instead: Check omega 3 claims before buying Book your treatment review

  What the trials found

  • A 2023 Cochrane review of 37 trials found no difference from placebo in parent-rated total ADHD symptoms over the medium term, and rated that result high certainty.
  • The 2025 EBI reanalysis, 15 trials involving 963 young people, found an effect close to zero at low certainty.
  • A hint that more children might be rated as improved rests on only three trials, also low certainty, so it does not make supplements an established treatment.

  Sources

  • Tier 1 guidelinePolyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescentsCochrane, 2023
  • Tier 1 guidelineBenefits and harms of ADHD interventions: umbrella review and platform for shared decision makingBMJ, 2025
  • Tier 1 guidelineSupplementary materials for EBI-ADHDGosling et al., EBI-ADHD team (BMJ 2025 supplement), 2025
• Not supported

  You will grow out of ADHD

  Not rated

  Symptoms can ease or fluctuate; growing up doesn't reliably bring permanent recovery.

  What holds up instead: Plan the move to adult ADHD care Ask for an adult ADHD assessment

  What the trials found

  • In the MTA follow-up of 558 children with ADHD, only 9.1% were in sustained remission at the young-adult endpoint, and 63.8% went through fluctuating periods of remission and recurrence.
  • They were a clinical childhood cohort, so those percentages are not a forecast for every child.
  • NIMH confirms that symptoms often continue into adulthood.

  Sources

  • Tier 2 studyVariable Patterns of Remission From ADHD in the Multimodal Treatment Study of ADHDAmerican Journal of Psychiatry, 2022
  • Tier 1 guidelineAttention Deficit/Hyperactivity Disorder: What You Need to KnowNIMH, 2024
• Not supported

  Taking prescribed stimulants leads to later addiction

  Not rated

  Prescribed treatment has not been linked to more substance misuse later. Misusing stimulants is a separate risk.

  What holds up instead: Discuss substance risk with your team Book your treatment review

  What the trials found

  • In a Swedish register study of 38,753 people with ADHD, those prescribed ADHD medication showed no increase in later substance abuse, counted as substance-related deaths, crimes or hospital visits, and their rate was 31% lower.
  • A meta-analysis of 15 longitudinal studies with 2,565 participants found that childhood stimulant treatment neither raised nor lowered the risk of later substance use problems.
  • Both are observational, so neither can prove protection, and misusing or sharing medication is a separate risk worth raising with the prescriber.

  Sources

  • Tier 2 studyStimulant ADHD medication and risk for substance abuseJournal of Child Psychology and Psychiatry, 2014
  • Tier 2 studyStimulant medication and substance use outcomes: a meta-analysisJAMA Psychiatry, 2013
• No better than placebo

  Homeopathy treats ADHD symptoms

  Very low certainty

  Trials haven't found benefit beyond control treatment; evidence is very uncertain.

  What holds up instead: Ask for a diagnosis explanation

  What the trials found

  • Cochrane found no convincing improvement in core ADHD symptoms.
  • The 2025 EBI reanalysis, two short term comparisons involving 63 children, found an effect close to zero, with a wide confidence interval and very low certainty.
  • So a benefit has not been demonstrated, which is not the same as proving every possible effect has been excluded.

  Sources

  • Tier 1 guidelineHomeopathy for ADHDCochrane, 2007
  • Tier 1 guidelineBenefits and harms of ADHD interventions: umbrella review and platform for shared decision makingBMJ, 2025
  • Tier 1 guidelineSupplementary materials for EBI-ADHDGosling et al., EBI-ADHD team (BMJ 2025 supplement), 2025
• Not supported

  Brain training apps reliably treat overall ADHD symptoms

  Low certainty

  Training can improve practised skills without reliably improving overall ADHD symptoms.

  What holds up instead: Make time visible Capture tasks in one place

  What the trials found

  • Across seven trials involving 395 young people, the EBI reanalysis found no clear short term improvement in overall symptoms rated by teachers, with low certainty.
  • A separate synthesis found working memory gains and small improvements in inattention that depended on the setting, but no clear benefit for total ADHD symptoms.
  • All of this is about cognitive training, not every digital therapy or practical reminder app.

  Sources

  • Tier 2 studyComputerized cognitive training in attention-deficit/hyperactivity disorder (ADHD): a meta-analysis of randomized controlled trials with blinded and objective outcomesMolecular Psychiatry, 2023
  • Tier 1 guidelineBenefits and harms of ADHD interventions: umbrella review and platform for shared decision makingBMJ, 2025
  • Tier 1 guidelineSupplementary materials for EBI-ADHDGosling et al., EBI-ADHD team (BMJ 2025 supplement), 2025
• Not supported

  Neurofeedback is a proven treatment for ADHD symptoms

  Low certainty

  Reported benefit doesn't consistently hold up when raters don't know the treatment.

  What holds up instead: Ask for a diagnosis explanation

  What the trials found

  • The 2025 meta-analysis found no meaningful overall symptom benefit when assessors were thought to be unaware of treatment allocation, although trials using established standard protocols showed a small benefit.
  • Across ten youth trials involving 587 participants, EBI found no clear short term benefit in teacher ratings, with low certainty, while parent ratings, from parents who knew about the treatment, did improve, with very low certainty.
  • None of this rules out every individual benefit, but it does not establish neurofeedback as a reliable standalone ADHD treatment.

  Sources

  • Tier 2 studyNeurofeedback for Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-AnalysisJAMA Psychiatry, 2025
  • Tier 1 guidelineBenefits and harms of ADHD interventions: umbrella review and platform for shared decision makingBMJ, 2025
  • Tier 1 guidelineSupplementary materials for EBI-ADHDGosling et al., EBI-ADHD team (BMJ 2025 supplement), 2025
• Unclear

  A strict elimination diet treats ADHD

  Very low certainty

  Some children may respond, but routine restrictive diets aren't established ADHD treatment.

  What holds up instead: Make regular meals easier

  What the trials found

  • EBI combined four short term trials involving 218 young people: the average estimate was large, but the confidence interval included no benefit and certainty was very low.
  • Earlier blinded analyses also failed to establish a general benefit from broad elimination diets, though some dietary studies selected children with suspected food sensitivities.
  • Individual responses remain possible, but that is no evidence that everyone with ADHD should cut out whole food groups.

  Sources

  • Tier 1 guidelineBenefits and harms of ADHD interventions: umbrella review and platform for shared decision makingBMJ, 2025
  • Tier 1 guidelineSupplementary materials for EBI-ADHDGosling et al., EBI-ADHD team (BMJ 2025 supplement), 2025
  • Tier 2 studyNonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatmentsAmerican Journal of Psychiatry, 2013
  • Tier 1 guidelineADHD in children and young peopleNHS, 2025
• Unclear

  Removing food colouring treats ADHD

  Not rated

  Plausible small effects in some children; reliable benefit for all isn't established.

  What holds up instead: Make regular meals easier

  What the trials found

  • A meta-analysis found a small average effect of synthetic food colours in parent ratings, which shrank after adjusting for possible publication bias, and no clear effect in the overall teacher or observer analysis.
  • Some attention tests and selected analyses did show effects, and a separate review found a benefit from excluding colours that held up in blinded ratings, but mostly in children selected for suspected food sensitivity.
  • A change in a subgroup doesn't show that food colouring explains ADHD generally.

  Sources

  • Tier 2 studyMeta-Analysis of Attention-Deficit/Hyperactivity Disorder or Attention-Deficit/Hyperactivity Disorder Symptoms, Restriction Diet, and Synthetic Food Color AdditivesJournal of the American Academy of Child and Adolescent Psychiatry, 2012
  • Tier 2 studyNonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatmentsAmerican Journal of Psychiatry, 2013
• Not supported

  Only boys have ADHD

  Not rated

  Girls and women have ADHD too; less visible difficulties can be missed.

  What holds up instead: Ask for an adult ADHD assessment Request your child's ADHD assessment

  What the trials found

  • In US survey data for 2022 to 2023, 7% of girls had an ADHD diagnosis against 13% of boys.
  • NHS guidance notes that girls may have more inattentive symptoms, which are harder to recognise.
  • Diagnosis rests on persistent symptoms and impairment, not on fitting the stereotype of a disruptive boy.

  Sources

  • Tier 1 guidelineData on ADHD in ChildrenCDC, 2026
  • Tier 1 guidelineADHD in children and young peopleNHS, 2025
• Not supported

  Caffeine is an effective ADHD treatment

  Not rated

  Small child trials haven't established symptom benefit and can't speak for adults.

  What holds up instead: Review caffeine and sleep together

  What the trials found

  • A 2023 review found seven small randomised trials involving 104 children, and four of those trials, with 76 participants, fed the overall symptom meta-analysis.
  • That analysis found no clear difference from placebo, although individual findings varied.
  • Evidence this small, all from children, does not justify using caffeine in place of clinician-guided ADHD care, or assuming the same result has been established in adults.

  Sources

  • Tier 2 studyEffects of Caffeine on Main Symptoms in Children with ADHD: A Systematic Review and Meta-Analysis of Randomized TrialsBrain Sciences, 2023
  • Tier 1 guidelineAttention Deficit/Hyperactivity Disorder: What You Need to KnowNIMH, 2024
• Not supported

  A TikTok symptom list can tell you that you have ADHD

  Not rated

  A relatable video can prompt useful questions. It cannot establish a diagnosis.

  What holds up instead: Check ADHD claims before sharing Ask for an adult ADHD assessment

  What the trials found

  • In a 2022 study of 100 popular ADHD TikTok videos, clinicians classed 52% as misleading, 27% as personal experience and 21% as useful, and those figures describe that sample, not all TikTok content.
  • A 2025 analysis also found that fewer than half of the symptom claims in its sample matched diagnostic criteria.
  • A clinical assessment weighs childhood onset, impairment in multiple settings and alternative explanations, none of which a relatable symptom list can establish.

  Sources

  • Tier 3 secondaryTikTok and Attention-Deficit/Hyperactivity Disorder: A Cross-Sectional Study of Social Media Content QualityCanadian Journal of Psychiatry, 2022
  • Tier 3 secondaryA double-edged hashtag: Evaluation of #ADHD-related TikTok content and its associations with perceptions of ADHDPLOS ONE, 2025
  • Tier 1 guidelineAttention Deficit/Hyperactivity Disorder: What You Need to KnowNIMH, 2024
• Not supported

  A genetic panel can pick the best ADHD medicine for your child

  Not rated

  Broad matching outruns the evidence; specific genetic results can sometimes inform prescribing.

  What holds up instead: Plan titration with your clinician

  What the trials found

  • The AAP guideline does not recommend pharmacogenetic tools for choosing ADHD medication, because their clinical usefulness has not been established.
  • A narrower exception is CYP2D6 information for atomoxetine metabolism, where CPIC gives guidance on interpreting a result someone already has.
  • That specific link does not validate a commercial panel promising to identify the best ADHD medicine, and medication decisions still need a prescriber and clinical monitoring.

  Sources

  • Tier 1 guidelineClinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and AdolescentsAmerican Academy of Pediatrics, 2019
  • Tier 2 studyClinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 Genotype and Atomoxetine TherapyClinical Pharmacology and Therapeutics, 2019
• Unclear

  Magnetic brain stimulation is a proven ADHD treatment

  Very low certainty

  Small studies have not shown a reliable overall symptom benefit from rTMS.

  What holds up instead: Ask for a diagnosis explanation

  What the trials found

  • The EBI reanalysis of four short term adult trials involving 118 participants found an effect close to zero on self-rated symptoms, with a wide confidence interval and very low certainty.
  • A separate sham-controlled meta-analysis found no clear overall benefit, but reported possible improvements in inattention and with particular stimulation targets.
  • Those signals still need confirming, and they do not establish rTMS as routine ADHD care.

  Sources

  • Tier 1 guidelineBenefits and harms of ADHD interventions: umbrella review and platform for shared decision makingBMJ, 2025
  • Tier 1 guidelineSupplementary materials for EBI-ADHDGosling et al., EBI-ADHD team (BMJ 2025 supplement), 2025
  • Tier 2 studyA meta-analysis of randomized sham-controlled trials of repetitive transcranial magnetic stimulation for attention deficit/hyperactivity disorderBrazilian Journal of Psychiatry, 2024
  • Tier 2 studyComparative efficacy and acceptability of pharmacological, psychological, and neurostimulatory interventions for ADHD in adults: a systematic review and component network meta-analysisThe Lancet Psychiatry, 2025
• Not supported

  Chiropractic adjustments treat ADHD symptoms

  Not rated

  No good evidence; a small recent trial found no advantage over sham.

  What holds up instead: Ask for a diagnosis explanation

  What the trials found

  • A systematic review found no eligible trials of good enough methodological quality to establish benefit for children with ADHD.
  • In a later pilot trial, 67 children were randomised and 56 were analysed, and adjustments plus usual care showed no significant symptom differences from sham adjustments plus usual care.
  • The trial was small, so it cannot rule out every effect, but it does not establish chiropractic treatment for ADHD.

  Sources

  • Tier 2 studyChiropractic care for paediatric and adolescent Attention-Deficit/Hyperactivity Disorder: A systematic reviewChiropractic and Osteopathy, 2010
  • Tier 3 secondaryThe effects of chiropractic adjustment on inattention, hyperactivity, and impulsivity in children with attention deficit hyperactivity disorder: a pilot RCTFrontiers in Psychology, 2024

The numbers behind many of these are on the evidence map.